Platinum exposure and cause-specific mortality among patients with testicular cancer by Groot, Harmke J et al.
 
 
 University of Groningen
Platinum exposure and cause-specific mortality among patients with testicular cancer
Groot, Harmke J; van Leeuwen, Flora E; Lubberts, Sjoukje; Horenblas, Simon; de Wit,
Ronald; Witjes, J Alfred; Groenewegen, Gerard; Poortmans, Philip M; Hulshof, Maarten C C





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Groot, H. J., van Leeuwen, F. E., Lubberts, S., Horenblas, S., de Wit, R., Witjes, J. A., Groenewegen, G.,
Poortmans, P. M., Hulshof, M. C. C. M., Meijer, O. W. M., de Jong, I. J., van den Berg, H. A., Smilde, T. J.,
Vanneste, B. G. L., Aarts, M. J. B., Jóźwiak, K., van den Belt-Dusebout, A. W., Gietema, J. A., &
Schaapveld, M. (2020). Platinum exposure and cause-specific mortality among patients with testicular
cancer. Cancer, 126(3), 628-639. https://doi.org/10.1002/cncr.32538
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
1Cancer  Month 0, 2019
Original Article
Platinum Exposure and Cause-Specific Mortality Among 
Patients With Testicular Cancer
Harmke J. Groot, MSc 1; Flora E. van Leeuwen, PhD1; Sjoukje Lubberts, MD2; Simon Horenblas, MD3; Ronald de Wit, MD4; 
J. Alfred Witjes, MD5; Gerard Groenewegen, MD6; Philip M. Poortmans, MD7,8; Maarten C. C. M. Hulshof, MD9;  
Otto W. M. Meijer, MD10; Igle J. de Jong, MD11; Hetty A. van den Berg, MD12; Tineke J. Smilde, MD13; Ben G. L. Vanneste, MD14; 
Maureen J. B. Aarts, MD15; Katarzyna Jóźwiak, PhD16,17; Alexandra W. van den Belt-Dusebout, PhD1; Jourik A. Gietema, MD2; 
and Michael Schaapveld, PhD1
BACKGROUND: Although testicular cancer (TC) treatment has been associated with severe late morbidities, including second malignant 
neoplasms (SMNs) and ischemic heart disease (IHD), cause-specific excess mortality has been rarely studied among patients treated 
in the platinum era. METHODS: In a large, multicenter cohort including 6042 patients with TC treated between 1976 and 2006, cause-
specific mortality was compared with general population mortality rates. Associations with treatment were assessed with proportional 
hazards analysis. RESULTS: With a median follow-up of 17.6 years, 800 patients died; 40.3% of these patients died because of TC. The 
cumulative mortality was 9.6% (95% confidence interval [CI], 8.5%-10.7%) 25 years after TC treatment. In comparison with general popu-
lation mortality rates, patients with nonseminoma experienced 2.0 to 11.6 times elevated mortality from lung, stomach, pancreatic, rectal, 
and kidney cancers, soft-tissue sarcomas, and leukemia; 1.9-fold increased mortality (95% CI, 1.3-2.8) from IHD; and 3.9-fold increased 
mortality (95% CI, 1.5-8.4) from pneumonia. Seminoma patients experienced 2.5 to 4.6 times increased mortality from stomach, pan-
creatic, bladder cancer and leukemia. Radiotherapy and chemotherapy were associated with 2.1 (95% CI, 1.8-2.5) and 2.5 times higher 
SMN mortality (95% CI, 2.0-3.1), respectively, in comparison with the general population. In a multivariable analysis, patients treated 
with platinum-containing chemotherapy had a 2.5-fold increased hazard ratio (HR; 95% CI, 1.8-3.5) for SMN mortality in comparison 
with patients without platinum-containing chemotherapy. The HR for SMN mortality increased 0.29 (95% CI, 0.19-0.39) per 100 mg/m2 
platinum dose administered (Ptrend < .001). IHD mortality was increased 2.1-fold (95% CI, 1.5-4.2) after platinum-containing chemotherapy 
in comparison with patients without platinum exposure. CONCLUSIONS: Platinum-containing chemotherapy is associated with a dose-
dependent increase in the risk of SMN mortality. Cancer 2019;0:1-12. © 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on 
behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial 
License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used 
for commercial purposes. 
KEYWORDS: cause-specific mortality, cisplatin, epidemiology, platinum, survivorship, testicular cancer.
INTRODUCTION
The prognosis of testicular cancer (TC) has greatly improved since the late 1970s because of the introduction of 
cisplatin-containing combination chemotherapy for disseminated TC, improvements in radiation techniques, and better 
supportive care.1,2 Currently, in Europe, the 10-year TC-specific survival is higher than 95%.1
TC treatment may, however, cause detrimental long-term health effects for TC survivors. Previous studies have 
shown that radiotherapy is associated with increased morbidity3-7 and mortality from second malignant neoplasms 
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(SMNs).6-8 A recent study from our group observed that 
chemotherapy was associated with SMN incidence as 
well.9 Chemotherapy has been associated with increased 
cardiovascular disease (CVD) morbidity10-13 and excess 
CVD mortality,6,14,15 but the data are less consistent.
Few studies have assessed long-term cause-specific 
excess mortality after TC treatment. In a large, inter-
national cohort study including 1-year TC survivors 
(n = 38,907), Fossa et al15 observed 1.4-fold increased 
CVD mortality after chemotherapy among patients 
treated between 1943 and 2002. More recently, among 
US patients treated between 1980 and 2010, Fung et al14 
found increased CVD mortality only in the first year after 
chemotherapy for nonseminoma. They also reported 
increased mortality due to pneumonia and influenza in 
comparison with the general population, whereas Fossa 
et al observed an increased risk of death due to fibrosis 
and pneumonitis.14,15
Since the 1980s, TC treatment intensity has gradu-
ally been reduced with decreases in the radiotherapy field 
size and dose among patients with seminoma, with the 
introduction of surveillance for stage I disease, and with 
fewer cycles of chemotherapy for patients with nonsem-
inoma.2,10,16,17 The impact of these changes on cause- 
specific excess mortality among more recently treated 
TC survivors is not yet clear. Therefore, we examined 
cause-specific mortality within a large, multicenter Dutch 
cohort of patients with TC diagnosed in the cisplatin era 
between 1976 and 2006.
MATERIALS AND METHODS
Study Population and Design
A hospital-based cohort was established that included 
6124 patients with TC who were younger than 50 years 
at their TC diagnosis and were treated in 13 Dutch hos-
pitals between 1976 and 2006 (Supporting Fig. 1).5-8,10 
The primary treatment was known for all patients. For 
efficiency reasons, we used a case-cohort design to facili-
tate detailed treatment data collection while allowing the 
assessment of multiple outcomes.18 A hospital-stratified 
subcohort composing 15% of the base cohort (25% in 
the coordinating hospitals Antoni van Leeuwenhoek and 
University Medical Center Groningen) was randomly 
selected. Before the analysis, 82 patients without follow-
up for vital status were excluded, and this left 6042 
patients in the full cohort and 1138 patients in the ran-
domly selected subcohort for analysis.
We established vital status up to July 2016 for 
93.7% of the patients through linkage with the Dutch 
Central Bureau for Genealogy, which collects genea-
logic information on all Dutch inhabitants, including 
the date of death. For 378 patients (6.3%), the link-
age failed, and the vital status was obtained from the 
patient’s general practitioner (GP) and/or tumor registries. 
Information on the cause of death was retrieved from 
hospital tumor registries, the patient’s medical chart, and 
the GP and through linkage with the nationwide cause of 
death registry at Statistics Netherlands up to January 1, 
2016. Direct and indirect causes of death were (re)coded 
according to the International Classification of Diseases, 
Tenth Revision.
For all patients in the subcohort and for all patients 
who had developed a predefined event (SMN, including 
contralateral TC; ischemic heart disease [IHD]; heart fail-
ure; or diabetes mellitus) and were not part of the sub-
cohort, detailed treatment data were abstracted from the 
medical charts; these data included chemotherapy regi-
mens, cumulative doses and numbers of cycles, and ra-
diotherapy fields and doses for primary treatment as well 
as relapse treatment. The study protocol was submitted to 
the institutional review board of the Netherlands Cancer 
Institute, which waived the requirement for individual 
patient consent.
All patients underwent an orchidectomy. For ear-
ly-stage seminoma, orchidectomy was usually followed by 
radiotherapy,16-19 which was typically given to the infra-
diaphragmatic para-aortic, ipsilateral iliac, and inguinal 
lymph nodes, with doses to delineated treatment fields 
ranging from 30 to 35 Gy. Since the mid-1980s, radi-
ation doses have gradually decreased to 26 to 32 Gy.19 
Patients with stage II to IV seminoma and nonseminoma 
were primarily treated with cisplatin-containing combi-
nation chemotherapy (initially with cisplatin, vinblastine, 
and bleomycin and since the mid-1980s with bleomycin, 
etoposide, and cisplatin [BEP]).20 Although rare, 1.8% of 
the patients (n = 10) in the subcohort who were treated 
with chemotherapy (mainly patients with nonseminoma) 
were treated with vinblastine, bleomycin, dactinomycin, 
or a combination of these drugs between 1976 and 1980. 
Surveillance after orchidectomy was standard treatment 
for stage I nonseminoma from 1984 onward in most 
hospitals.21
Statistical Analysis
The time at risk started at the TC diagnosis and ended at 
the date of death, the date of emigration, or January 1, 
2016 (whichever came first). Mortality rates among pa-
tients with TC were compared with age-specific, calendar 
period–specific, and site-specific cancer mortality rates in 
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the Dutch male population. Standardized mortality ratios 
(SMRs), absolute excess mortality (expressed per 10,000 
person-years), and corresponding 95% confidence inter-
vals (CIs) were computed with standard methods and are 
reported for the full cohort.18 General population mortal-
ity data from Statistics Netherlands for 1976-2015 were 
used as reference rates. Unless otherwise stated, TC mor-
tality was excluded from analyses. Tests for homogene-
ity and trends of SMRs were performed within collapsed 
person-time Poisson regression models; models were ad-
justed for age unless specified otherwise.22
Missing information on stage (7.5%), primary and 
follow-up treatment (radiotherapy [0.8%], radiotherapy 
field [13.5%], radiotherapy dose [11.8%], chemotherapy 
[0.8%], chemotherapy regimen [5.1%], and number of 
cycles [11.3%]), and weight, height, and smoking status 
at the TC diagnosis (11.9%) were imputed for the cases 
and subcohort members via ordered multiple imputation 
by chained equations with 20 data sets and with patient 
clusters ignored.19,20 Our results are based on adminis-
tered chemotherapy and radiation doses. Multinomial 
models and linear regression models were used for im-
putation; the year and age at treatment, histology, age, 
hospital, and cause-specific cumulative hazards of mortal-
ity calculated with a Cox regression model before impu-
tation were included as extra covariates.20 Because of the 
amount of missing data on body size area and cumulative 
platinum dose, we based the administered platinum dose 
on the number of administered cycles, which agreed well 
with actual cumulative administered doses in milligrams 
per meter squared of body surface area in patients without 
missing data.
Cumulative mortality was estimated with death 
due to TC as a competing risk,23 and trends over time 
were evaluated via competing risk regression models with 
adjustments for the age at TC diagnosis. Multivariable 
proportional hazards models were used to assess associ-
ations of TC treatment with cause-specific mortality. 
The time since TC treatment was used as the time scale, 
and the partial likelihood function was adjusted for the 
case-cohort analysis with Barlow’s inverse probability 
weights.18-23 Treatment was included time-dependently, 
and this allowed a patient to add person-time to a differ-
ent treatment category at the date on which treatment for 
relapsed or contralateral TC was initiated.23 All analyses 
were adjusted for age and smoking unless stated other-
wise. For a sensitivity analysis, we evaluated the effect of 
clustering of patients within a treatment center by add-
ing a clustering term to the Cox models, and we adjusted 
the variance for within-treatment center clustering. To 
assess excess relative risk by the administered treatment 
dose, the linear increase in the hazard ratio (HR) for 
dose categories (estimated from a Cox model with the 
category value set at the median dose within that cate-
gory) was estimated via variance-weighted least squares 
regression with weights equal to 1/variance of the HR 
for each imputed data set. We assessed dose-response 
relationships by first modeling the cause-specific HRs 
as HR = 1 + β(dose), where β is the proportional 
increase in the HR per unit increase in dose. We evaluated a 
departure from linearity by including a quadratic dose 
term in the model HR = 1 + β(dose) + Φ(dose)2 and 
testing whether the coefficient for the quadratic dose term 
was Φ = 0. Regression model estimates were pooled with 
Rubin’s rule.24,25 The proportional hazards assumption 
was assessed with residual-based methods. Standard errors 
are reported as robust standard errors. A P value ≤ .05 
was considered significant. Stata statistical software 
(StataCorp LP, College Station, Texas; 2013) was used for 
analysis.
RESULTS
The cohort comprised 2875 patients with seminoma and 
3167 patients with nonseminoma (Table 1 and Supporting 
Fig. 1). The median age of patients with seminoma was 
35.0 years (interquartile range [IQR], 30.4-40.4 years), 
whereas the median age of patients with nonseminoma 
was 27.7 years (IQR, 23.3-33.6 years; P < .001). The 
median follow-up was 17.6 years (IQR, 12.2-24.2 years); 
22.7% of the patients were followed 25 years or longer.
Comparisons With the General Population
The cause of death was available for 96.1% of all 800 pa-
tients who had died up to January 1, 2016 (Table 2). Of 
these 800 patients, 322 (40.3%) died of TC, 226 (28.3%) 
died of SMNs other than TC, and 104 (13.0%) died of 
diseases of the circulatory system. Non-TC mortality 
was 1.4-fold increased (95% CI, 1.3-1.6) in comparison 
with general population mortality rates. We observed 
28.9 excess deaths from TC (95% CI, 25.8-32.3) and 
13.0 excess deaths due to causes other than TC (95% 
CI, 9.1-17.1) per 10,000 person-years of follow-up. 
In the univariate analysis, SMRs for non-TC mortality 
decreased among older patients (Ptrend < .001; Supporting 
Tables 1 and 2). SMRs for non-TC mortality and SMN 
mortality remained increased even 20 or more years after 
treatment in comparison with general population rates, 
without a clear trend in SMRs (Ptrend = .24 for non-TC 
mortality; Ptrend = .49 for SMN mortality; Supporting 
Table 1). Adjusted for age and follow-up duration, 
Original Article
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SMRs for non-TC mortality and SMN mortality did not 
decrease among more recently treated patients (1996-
2007) in comparison with those treated between 1976 
and 1985 and between 1986 and 1995 (Ptrend = .49 
for non-TC mortality; Ptrend = .80 for SMN mortality; 
Supporting Table 3). However, SMRs for noncancer mor-
tality did decrease over time (P < .001).
Neither SMN mortality nor IHD mortality was 
increased among patients treated with surgery only 
(Supporting Table 4). Primary radiotherapy was associ-
ated with increased SMN mortality (SMR, 2.1; 95% CI, 
1.8-2.5), especially due to colorectal, pancreatic, and uro-
logic SMNs, but not with noncancer mortality. Primary 
chemotherapy was also associated with increased SMN 
mortality (SMR, 2.5; 95% CI, 2.0-3.1) and specifically 
with increased mortality from lung, colorectal, and non-
colorectal gastrointestinal (GI) SMNs and leukemia. The 
receipt of chemotherapy was also associated with a 2.1-
fold increased SMR for IHD (95% CI, 1.3-3.2) and a 
2.8-fold increased SMR for respiratory diseases (95% CI, 
1.3-5.1).
For patients with seminoma, non-TC mortality was 
1.3-fold increased (95% CI, 1.1-1.4). SMN mortality was 
significantly elevated (116 deaths; SMR, 1.6), particularly 
because of SMNs of the pancreas (18 deaths; SMR, 4.6), 
stomach (7 deaths; SMR, 2.5), and bladder (6 deaths; 
SMR, 4.4) and leukemia (6 deaths; SMR, 3.2; Table 2). 
Mortality due to urogenital diseases (5 deaths; SMR, 
3.6) was also increased, and this mainly reflected deaths 
from chronic kidney diseases. For patients with nonsem-
inoma, non-TC mortality was 1.7-fold higher than ex-
pected (95% CI, 1.5-1.9; Table 2) and did not decrease 
among more recently treated patients (Ptrend = .96 for 
treatment period; Supporting Table 2). SMN mortality 
was significantly elevated (110 deaths; SMR, 2.3), par-
ticularly because of SMNs of the lungs (26 deaths; SMR, 
2.0), esophagus (6 deaths; SMR, 2.8), stomach (6 deaths; 
SMR, 3.2), pancreas (7 deaths; SMR, 2.7), rectum 
(6 deaths; SMR, 4.8), and kidneys (7 deaths; SMR, 5.9), 
soft-tissue sarcomas (6 deaths; SMR, 11.6), and leukemia 
(6 deaths; SMR, 4.1; Table 2). Patients with nonsemi-
noma also experienced increased mortality from IHD (29 
deaths; SMR, 1.9) and pneumonia (6 deaths; SMR, 3.9). 
Additional analysis showed that the SMR for soft-tissue 
sarcoma was increased 7.6-fold (95% CI, 1.6-22.3) after 
1 to 5 years of follow-up and 6.9-fold (95% CI, 2.2-16.2) 
after 5 or more years of follow-up in all TC survivors. 
However, these analyses are based on fewer than 10 cases.
TABLE 1. Baseline Characteristics for Patients With Testicular Cancer Treated Between 1976 and 2006
Characteristic Cohort (n = 6042) Seminoma (n = 2875) Nonseminoma (n = 3167)
Age at diagnosis, median (IQR), y 31.7 (25.8-37.7) 35.0 (30.4-40.4) 27.7 (23.3-33.6)
Age at diagnosis, No. (%)
<20 y 330 (5.5) 21 (0.7) 309 (9.8)
20-29 y 2269 (37.6) 657 (22.9) 1612 (50.9)
30-39 y 2381 (39.4) 1431 (49.8) 950 (30.0)
40-49 y 1062 (17.6) 766 (26.4) 296 (9.4)
Treatment period, No. (%)
1975-1985 968 (16.0) 346 (12.0) 622 (19.6)
1986-1995 1902 (31.5) 871 (30.3) 1031 (32.6)
1996-2006 3172 (52.5) 1658 (57.7) 1514 (47.8)
Primary treatment, No. (%)
Orchidectomy only 1450 (24.0) 401 (14.0) 1049 (33.1)
Radiotherapy ± chemotherapya 2255 (37.3) 2086 (72.6) 169 (5.3)
Chemotherapy only 2337 (38.7) 388 (13.5) 1949 (61.5)
Vital status (up to January 1, 2016), No. (%)
Alive 5145 (85.2) 2532 (88.1) 2613 (82.5)
Died 800 (13.2) 297 (10.3) 503 (15.9)
Emigrated 97 (1.6) 46 (1.6) 51 (1.6)
Follow-up, median (IQR), y 17.6 (12.2-24.2) 16.9 (12.3-23.2) 18.2 (12.1-25.3)
Follow-up, No. (%)
<1 y 167 (2.8) 38 (1.3) 129 (5.1)
1-4 y 206 (3.4) 56 (1.9) 150 (4.7)
5-9 y 492 (8.1) 250 (8.7) 242 (7.6)
10-14 y 1456 (24.1) 805 (28.0) 651 (20.6)
15-19 y 1281 (21.2) 656 (22.8) 626 (19.7)
20-24 y 1067 (17.7) 519 (18.1) 548 (17.3)
≥25 y 1373 (22.7) 551 (19.2) 822 (26.0)
Attained age at end of follow-up, median (IQR), y 50.4 (43.0-57.8) 53.0 (46.4-60.3) 47.6 (39.2-55.2)
Abbreviation: IQR, interquartile range.
aOne hundred sixteen patients (1.92%) had both radiotherapy and chemotherapy.
Mortality After Testicular Cancer Treatment/Groot et al
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Cumulative Mortality
The cumulative mortality was 9.6% (95% CI, 8.5%-
10.7%) 25 years after TC treatment (Fig. 1). Cumulative 
mortality was lower for more recently treated patients 
(Ptrend = .026). The 15- and 25-year SMN mortality 
rates were 1.2% (95% CI, 0.6%-2.0%) and 5.1% (95% 
CI, 3.8%-6.7%), respectively, in 1976-1985 and 2.1% 
(95% CI, 0.8%-1.8%) and 4.1% (95% CI, 3.2%-5.2%), 
respectively, in 1986-1995, whereas the 15-year cumula-
tive mortality rate was 1.6% (95% CI, 1.1%-2.1%) in 
1996-2006 (Supporting Fig. 2). Correspondingly, CVD 
mortality was 1.5% (95% CI, 0.9%-2.4%) and 3.7% 
(95% CI, 2.6%-5.0%) in 1976-1985 and 0.5% (95% CI, 
0.3%-0.9%) and 1.8% (95% CI, 1.2%-2.6%) in 1986-
1995 at 15 and 25 years, respectively, whereas the 15-year 
cumulative mortality was 1.7% (95% CI, 1.2%-2.3%) 
in 1996-2006. SMN mortality slightly decreased over 
time for both patients with seminoma (Ptrend = .052) and 
patients with nonseminoma (Ptrend = .012; Supporting 
Fig. 2). The 25-year cumulative mortality due to SMNs 
was 4.6% (95% CI, 3.9%-5.4%). The 25-year cumulative 
CVD mortality was low at 2.3% (95% CI, 1.8%-2.9%) 
and decreased among more recently treated patients 
(Ptrend < .001), including both patients with seminoma 
and patients with nonseminoma (Supporting Fig. 2). TC 
mortality decreased substantially until the mid-1980s, 
whereafter mortality seemed to stabilize (Supporting 
Fig. 3).
Cause-Specific Mortality and TC Treatment: 
Case-Cohort Analysis
In a multivariable analysis, platinum-containing chemo-
therapy was associated with 2.5 times increased SMN 
mortality (95% CI, 1.8-3.5) in comparison with sur-
gery only, whereas GI tract SMN mortality was 3.1-fold 
increased (95% CI, 1.7-5.7) among platinum-treated 
patients (Table 3). Both colorectal (Ptrend = .006) and 
noncolorectal GI tract SMN mortality (Ptrend < .001) 
increased with a higher dose of cisplatin-containing 
chemotherapy, with the receipt of platinum-containing 
chemotherapy at 400 to 499 and ≥500 mg/m2 being as-
sociated with 2.4 and 6.4 times increased noncolorectal 
GI cancer mortality, respectively, in comparison with pa-
tients not receiving platinum-containing chemotherapy. 
A dose-response relationship was observed between SMN 
mortality and the cumulative administered platinum 
dose in particular for GI tract SMNs (Fig. 2), with the 
HR for mortality due to any SMN increasing linearly by 
0.29 (95% CI, 0.19-0.39; Ptrend ≤ .001) per 100 mg/m
2  
administered platinum dose, whereas the HR for mortality 
due to GI tract SMNs linearly increased by 0.66 (95% 
CI, 0.35-0.99; Ptrend ≤ .001) per 100 mg/m
2 adminis-
tered platinum dose. Lung cancer mortality increased 1.9 
Figure 1. Cumulative mortality due to TC, all causes other than 
TC, second malignant neoplasms other than TC, causes other 
than cancer, and cardiovascular disease for (A) all patients with 
TC combined, (B) patients with seminoma, and (C) patients 
with nonseminoma. TC indicates testicular cancer.
Mortality After Testicular Cancer Treatment/Groot et al










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8 Cancer  Month 0, 2019
times (95% CI, 0.9-4.1) after chemotherapy and tended 
to increase with an increasing administered dose of plati-
num-containing chemotherapy (Ptrend = .076). Smoking 
at the TC diagnosis was an independent risk factor associ-
ated with 3.8 times increased lung cancer mortality (95% 
CI, 1.7-8.5). IHD mortality increased 2.1 times (95% 
CI, 1.5-4.2) after platinum-containing chemotherapy in 
comparison with patients without platinum exposure. 
IHD mortality also increased 3.4 times (95% CI, 1.4-8.3) 
among patients who smoked at the TC diagnosis.
The infradiaphragmatic radiation dose was also 
associated with increasing SMN mortality (Ptrend < .001). 
Noncolorectal GI tract SMN mortality also increased with 
a higher infradiaphragmatic radiation dose. The adminis-
tered infradiaphragmatic radiation dose showed a linear 
dose-response relationship, with the HR for any SMN 
increasing by 0.05 (95% CI, 0.03-0.07; Ptrend ≤ .001) 
and the HR for GI tract SMN mortality increasing by 
0.12 (95% CI, 0.09-0.15; Ptrend ≤ .001) per gray of radi-
ation administered (Fig. 3).
A complete case analysis, including only patients 
with nonmissing treatment data, showed similar results in 
comparison with the analysis incorporating imputed data. 
A sensitivity analysis with clustering on treatment cen-
ter showed similar results for treatment-associated risks 
(Supporting Table 5).
DISCUSSION
In this large, multicenter cohort of Dutch patients with 
TC treated between 1976 and 2006, we observed increased 
mortality from SMNs as well as causes other than can-
cer, particularly IHD. Although a few studies previously 
reported increased mortality from solid SMNs, leukemia, 
and CVD among patients with TC, our study is the first 
to report that an increasing administered platinum dose is 
associated with a linearly increasing risk of SMN mortal-
ity, particularly mortality due to GI cancer.6,8,15,26-28 Our 
study further adds to mortality estimates in previous stud-
ies by including primary and follow-up treatment and 
providing mortality risk estimates after more prolonged 
follow-up of patients treated with platinum-containing 
chemotherapy.
Both chemotherapy and radiotherapy have previ-
ously been associated with an increased risk of various 
solid SMNs, including GI and urologic malignan-
cies.5,6,19,26,29,30 Radiotherapy and chemotherapy were 
associated with SMN mortality (SMR for radiotherapy, 
2.1; 95% CI, 1.8-2.5; SMR for chemotherapy, 2.5; 95% 
CI, 2.0-3.1). Our observation of an increasing risk of 
mortality due to SMNs with a higher cumulative dose 
of platinum-based chemotherapy is consistent with a 
dose-dependent increase in the solid SMN incidence, 
which we recently reported.10 Kier et al6 also recently 
Figure 2. Mortality from (A) any SMNs and (B) gastrointestinal 
SMNs by the cumulative dose of platinum-containing CT (mg/m2 
of body surface area). HR estimates (ERRs) were derived 
from models adjusted for age (continuous), smoking at 
testicular cancer diagnosis, supradiaphragmatic radiotherapy, 
and subdiaphragmatic radiation dose. Circles represent HR 
estimates for dose categories (no platinum-containing CT and 
>0-399, 400-499, and ≥500 mg/m2 of body surface area) and 
are plotted at the median dose in each category (0, 300, 400, 
and 600  mg/m2, respectively). Dose-response relationships 
were based on the categorical dose as an outcome, with the 
category set at the median dose within that category. Vertical 
lines reflect the 95% CIs around the HRs for dose categories. 
The dashed line in panel A is the best fitting dose-response 
relationship and reflects a linear increase in the mortality risk 
from any SMN, with 0.29 (95% CI, 0.19-0.39; P <  .001) added 
to the HR for each additional platinum-containing CT dose of 
100 mg/m2 body surface area. The dashed line in panel B is 
the best fitting dose-response relationship and reflects a linear 
increase in gastrointestinal SMN mortality risk, with 0.66 (95% 
CI, 0.35-0.97; P <  .001) added to the HR for each additional 
platinum-containing CT dose of 100  mg/m2 of body surface 
area. CI indicates confidence interval; CT, chemotherapy; ERR, 
excess relative risk; HR, hazard ratio; SMN, second malignant 
neoplasm.
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reported 1.6-fold increased SMN mortality among pa-
tients with TC treated with platinum-containing che-
motherapy; risks were up to 5.8-fold increased among 
patients treated with multiple lines of treatment in com-
parison with general population controls. In their study, 
BEP chemotherapy was associated with increased mor-
tality from lung, esophageal, and bladder cancers, soft- 
tissue sarcomas, and myeloid leukemia. We confirm their 
findings, but our observations include renal cancer rather 
than bladder cancer.
Cisplatin has been classified as a carcinogenic com-
pound and acts by crosslinking DNA.31,32 Previously, 
increased GI cancer incidence among childhood cancer 
survivors has been reported after platinum exposure.33-35 
Exposure to platinum-containing chemotherapy has been 
suggested to cause GI polyposis in humans, although the 
causal mechanism has not yet been established.36
Increased mortality from soft-tissue sarcomas was 
observed among patients with nonseminoma. Our results 
are in line with those of Kier et al,6 who observed an in-
creased risk of soft-tissue sarcoma after the receipt of BEP 
(median time, 12 years), whereas no increased risks were 
observed after radiotherapy. Our soft-tissue sarcoma cases 
died after a median follow-up of 10.6 years after primary 
TC. We cannot exclude the idea that the high SMR for 
sarcomas is partly due to late relapses, however rare.37
Radiotherapy was also associated with increased 
mortality from non-TC SMNs, and mortality remained 
increased throughout follow-up. Previous studies, which 
largely consisted of patients treated before the 1980s, 
found a 1.5 to 1.9 times increased SMR from SMNs after 
radiotherapy.8,26,27 Excess mortality among irradiated 
patients with seminoma followed beyond 15 years is consis-
tent with a radiation effect.8,26 Robinson et al4 observed 
excess cancer mortality only within the first 5 years after 
the diagnosis among patients treated with modern radi-
ation techniques since the 1990s. A more recent Danish 
population-based study observed 2.1 times increased 
SMN mortality, particularly from stomach, pancreatic, 
prostate, and bladder cancers, after radiation for TC 
between 1984 and 2007.6 Except for prostate cancer, we 
also observed increased mortality for these malignancies 
in our patients with seminoma.
A substantial proportion of all cancer deaths in our 
cohort among patients with seminoma was attributable 
to pancreatic cancer (18 deaths; 31% of SMN-related 
excess deaths), a malignancy with a poor prognosis that 
has not improved much over the last decades. A recent 
study already reported a strongly increasing SMN risk 
with higher radiation doses to the pancreas (excess relative 
risk, 0.12 per gray of radiation).30 Because few patients 
with seminoma nowadays undergo para-aortic radiation 
and radiation doses for these patients are also generally 
lower (<26 Gy), radiation-associated pancreatic cancer 
mortality will likely decrease in the near future. On the 
Figure 3. Mortality from (A) SMNs and (B) gastrointestinal 
SMNs by the administered infradiaphragmatic RT dose. HR 
estimates (ERRs) were derived from models adjusted for 
age (continuous), smoking at testicular cancer diagnosis, 
supradiaphragmatic RT, and platinum dose. Dose-response 
relationships were based on the categorical dose as an 
outcome, with the category set at the median dose within 
that category. Circles represent estimates for dose categories 
(no infradiaphragmatic RT and >0-26, 27-32, 33-36  Gy, and 
>36 Gy) and are plotted at the median dose in each category 
(0, 26, 30, 36, and 40 Gy, respectively). Vertical lines denote 
the 95% CIs around the HRs for dose categories. The dashed 
line in panel A is the best fitting dose-response relationship 
and reflects a linear increase in SMN mortality, with 0.05 (95% 
CI, 0.03-0.07; P <  .001) added to the HR for each additional 
gray of infradiaphragmatic RT. The dashed line in panel B is 
the best fitting dose-response relationship and reflects a linear 
increase in gastrointestinal mortality, with 0.12 (95% CI, 0.09-
0.15; P < .001) added to the mortality rate for each additional 
gray of infradiaphragmatic RT. CI indicates confidence interval; 
ERR, excess relative risk; HR, hazard ratio; RT, radiotherapy; 
SMN, second malignant neoplasm.
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other hand, we recently reported that platinum-containing 
chemotherapy may also increase pancreatic cancer risk.9
IHD mortality was associated with the receipt of 
platinum-containing chemotherapy in our study. In line 
with our findings, chemotherapy exposure increased 
circulatory disease mortality 1.4-fold in a large, inter-
national registry–based study including 38,907 patients 
treated after 1975.15 Kier et al6 noted borderline signifi-
cantly increased circulatory disease mortality after the 
receipt of chemotherapy in comparison with the general 
population in Danish patients treated between 1984 
and 2007. Interestingly, Fung et al14 recently observed 
increased CVD mortality only during the first year of 
follow-up (based on only 6 cardiac deaths and 5 cerebro-
vascular disease deaths), although the median follow-up 
was only 6.5 years after chemotherapy in their study. 
Some case reports have described severe acute myocardial 
infarction38,39 or stroke shortly after chemotherapy in TC 
survivors,40 although these events are rare and usually not 
fatal. Differences in the underlying CVD risk factors, 
lifestyles, and prophylactic use of low-molecular-weight 
heparin to prevent platinum-associated thromboembolic 
events may underlie these heterogeneous findings with 
respect to CVD mortality.41,42
We found increased mortality from respiratory dis-
eases, particularly pneumonia, after exposure to chemo-
therapy in our cohort. Our results are in line with those of 
Fossa et al,15 who observed increased respiratory mortal-
ity due to lung fibrosis and pneumonitis among patients 
treated with primary chemotherapy after 1975. To our 
knowledge, bleomycin has not been associated with side 
effects other than lung fibrosis. Unfortunately, because 
the current study did not include sufficient numbers 
of patients who did not receive bleomycin (ie, patients 
treated with etoposide and platinum), we cannot com-
pletely ascribe the increased mortality risks to platinum 
exposure alone.
Strong features of the current study include its 
extended follow-up and the availability of detailed treat-
ment data. Using time-dependent Cox regression, we were 
able to more precisely allocate observation time to primary 
and follow-up treatment, and this increased the reliability 
of our results in comparison with other studies based on 
primary treatment only. Limitations include the lack of 
risk factors for cancer and cardiovascular mortality (ie, 
lifestyle and smoking), although smoking behavior in our 
cohort is not likely to differ from that of the general pop-
ulation.15 In addition, our analysis did not allow further 
analysis for genitourinary malignancies because of the low 
numbers of cases exposed to platinum. Despite our efforts 
to abstract compete treatment exposure information from 
the medical records, we had missing data on, among 
other things, the cumulative platinum dose and body 
size. However, because dose reductions were rare and the 
actual cumulative administered dose for patients for whom 
we had complete information on dose and body surface 
was highly comparable to the dose based on the number 
of administered cycles of chemotherapy, in all our analy-
ses, we approximated the cumulative platinum dose with 
the number of administered cycles of chemotherapy. We 
acknowledge that we present many significance tests and, 
therefore, caution against overinterpretation of our find-
ings, especially when they are based on P values > .001.
For 191 of the 226 patients (84.5%) who died of 
an SMN and for 31 of the 51 patients (60.8%) who died 
of IHD, detailed treatment data were available from the 
medical records. For most of the patients who had died 
of an SMN and for whom detailed treatment data were 
missing, the date of death was later than the date of last 
linkage with the Netherlands Cancer Registry and the 
date of last information from the GP. We also identified 
18 new fatal IHD events (among the 51 patients who 
died of IHD) among patients without a known IHD his-
tory. For these patients, either the GP had not responded 
to our request for information or the date of death was 
later than the date of the last medical information that 
we had received from the GP. In the Netherlands, unfor-
tunately, tracing back patients identified on the basis of 
data provided by the cause of death registry at Statistics 
Netherlands is not allowed because of the privacy laws. 
For these patients, treatment details were imputed.
Despite efforts to reduce the long-term toxicity 
of TC treatment, we observed no decrease in overall 
excess mortality or mortality due to cancers other than 
TC among more recently treated patients, although abso-
lute excess mortality only modestly increased after 1995. 
However, noncancer mortality decreased over time. Fossa 
et al15 previously reported a significantly increased SMR 
from causes other than cancer of 1.07 for patients treated 
before 1975 and of 1.04 for patients treated after 1975 in 
comparison with general population rates, and this indi-
cated only a small mortality reduction over time. Finally, 
treatment-associated mortality may be partly due to 
(interactions with) environmental and lifestyle factors 
that also operate in the general population.
In conclusion, TC survivors treated in the plat-
inum era experience increased mortality from SMNs 
in comparison with the general population, and this 
appears in part due to exposure to platinum-containing 
chemotherapy. This study also shows that exposure to 
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platinum-containing chemotherapy is associated not only 
with a dose-dependent increased SMN incidence but also 
increased mortality from SMNs. Future studies and more 
prolonged follow-up of patients treated more recently 
with 3 or fewer (B)EP cycles are needed to better assess 
whether low platinum doses indeed still increase the risk 
for non-TC mortality. In the meantime, potential strat-
egies toward risk reduction (ie, screening for malignan-
cies of the GI tract as well as [risk factors for] CVDs) are 
warranted among long-term survivors treated with higher 
doses of platinum or para-aortic radiation. In addition, 
through healthier lifestyle behaviors (particularly smoking 
cessation, reduction of alcohol intake, increased physical 
activity, and a healthy diet), mortality may be reduced.
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